Frequent Links
Aerodynamics Review ArticlesMaritime Security Operations High Impact FactorProteomics New FindingsJuvenile Justice Systemdrug resistant journalsdrug dependence journalsParticle Radiation Microbial Technology Top articles in Gait AnalysisEnvironmental microbiology Scholarly Peer-review JournalCell nucleus InnovationsepigeneticsMenopause review articlesMyalgic encephalomyelitis Pre-eclampsia impact factor
ROD-188
| File:ROD-188.png | |
| Systematic (IUPAC) name | |
|---|---|
| (5R)-5-{(1R)-2-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-1-yl}dihydrofuran-2(3H)-one | |
| Clinical data | |
| |
| Identifiers | |
| None | |
| PubChem | CID 9842377 |
| Chemical data | |
| Formula | C20H21NO4S |
| 371.449 g/mol | |
| |
| 14px (what is this?) (verify) | |
ROD-188 is a sedative drug that was structurally derived from the GABAA antagonist bicuculline by a team at Roche.[1] Unlike bicuculline, ROD-188 acts as an agonist at GABAA receptors, being a positive allosteric modulator acting at a novel binding site distinct from those of benzodiazepines, barbiturates or muscimol, with its strongest effect produced at the α6β2γ2 subtype of the GABAA receptor.[2] ROD-188 is one of a number of related compounds acting at this novel modulatory site, some of which also act at benzodiazepine receptors.[3]
See also
References
- ↑ US Patent 6649626 N-substituted 1-(lactone) isoquinolones for treating nervous disorders
- ↑ Thomet U, Baur R, Razet R, Dodd RH, Furtmüller R, Sieghart W, Sigel E. A novel positive allosteric modulator of the GABA(A) receptor: the action of (+)-ROD188. British Journal of Pharmacology. 2000 Oct;131(4):843-50. PMID 11030736
- ↑ Sigel E, Baur R, Furtmueller R, Razet R, Dodd RH, Sieghart W. Differential cross talk of ROD compounds with the benzodiazepine binding site. Molecular Pharmacology. 2001 Jun;59(6):1470-7. PMID 11353808
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lua error in package.lua at line 80: module 'Module:Buffer' not found.